Inventiva Pharma Overview

  • Status
  • Public
  • Employees
  • 94
Employees
  • Stock Symbol
  • IVA
Stock Symbol
  • Share Price
  • $13.63
  • (As of Friday Closing)

Inventiva Pharma General Information

Description

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France. The majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 50 rue de Dijon
  • 21121 Daix
  • France
+33 03 00 00 00 00

Inventiva Pharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inventiva Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.63 $13.46 $9.19 - $19.75 $526M 38.6M 36.2K -$1.13

Inventiva Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 507,949 507,949 70,370 55,439
Revenue 424 424 7,834 3,773
EBITDA (36,352) (36,352) (32,611) (37,838)
Net Income (38,323) (38,323) (33,827) (38,959)
Total Assets 170,867 170,867 63,805 91,297
Total Debt 16,302 16,302 2,355 2,520
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Inventiva Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial

Inventiva Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptor
Drug Discovery
Daix, France
94 As of 2020
00000
00000000 00000

0000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000 00000

00000 00

re magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000 000000000
Carlsbad, CA
000 As of 0000
0000
0.000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inventiva Pharma Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genocea Biosciences Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
00000 000000000000 Corporation Exton, PA 00 00000 000000000 00000
000000000 00000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
00000000 Venture Capital-Backed New Haven, CT 00 00000 00000000 00000
You’re viewing 5 of 46 competitors. Get the full list »

Inventiva Pharma Executive Team (6)

Name Title Board Seat Contact Info
Frédéric Cren Co-Founder, Chief Executive Officer and Chairman
Jean Volatier Chief Financial Officer, Finance
Pierre Broqua Ph.D Chief Scientific Officer & Founder
Michael Cooreman MD Chief Medical Officer
You’re viewing 4 of 6 executive team members. Get the full list »

Inventiva Pharma Board Members (6)

Name Representing Role Since
000000 00000000 00.0 Self Board Member 000 0000
00000 00000 Self Board Member 000 0000
00é0é000 0000 Inventiva Pharma Co-Founder, Chief Executive Officer and Chairman 000 0000
00000 0000000 Self Board Member 000 0000
0000 00 00 Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Inventiva Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inventiva Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial